Author:
Kostelidou Kalliopi,Sideri Anastasia,Lazaridis Konstantinos,Fostieri Efrosini,Tzartos Socrates J.
Reference188 articles.
1. Aarli, J. A. (1999) Late onset myasthenia gravis, a changing scene. Arch Neurol
56, 25–27
2. Aissaoui, A., Klingel-Schmitt, I., Couderc, J., Chateau, D., Romagne, F., Jambou, F., Vincent, A., Levasseur, P., Eymard, B., Maillot, M. C., Galanaud, P., Berrih-Aknin, S., and Cohen-Kaminsky, S. (1999) Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis. Ann Neurol
46, 559–567
3. Alberola-Ila, J., Takaki, S., Kerner, J. D., and Perlmutter, R. M. (1997) Differential signaling by lymphocyte antigen receptors. Annu Rev Immunol
15, 125–154
4. Allison, A. C., and Eugui, E. M. (2000) Mycophenolate mophetil ans its mechanisms of action. Immunopharmacology
47, 85–118
5. Anaya, J. M., and Espinoza, L. R. (1995) Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. J Rheumatol
22, 595–599